CARLSBAD, CA -
(Marketwired), 6/17/2014 - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based
biotechnology company developing novel stem cell based therapies and biomedical
products, today announced that Executive Vice President Dr. Simon Craw, will present
an overview of ISCO and its subsidiaries at the BIO 2014 conference on Tuesday,
June 24th at 4:15 pm PDT. The conference is being held at the San Diego
Convention Center.
BIO 2014 conference presentation details:
Date: Tuesday, June 24th 2014
Time: 4:15 pm PDT
Location: San
Diego Convention Center, San Diego, CA
Room: Mission
Beach
Conference
details: http://convention.bio.org/
BIO is the largest,
most influential biotech meeting in the world, regularly attracting 15,000 of
the most powerful biotech and pharm participants from 60+ countries. This year at the San Diego Convention Center,
June 23 – 26, 2014, the conference includes sessions and specialty forums
covering 17 hot topics, 1,700+ exhibitors and BIO One-on-One PartneringTM
meetings with thousands of companies. If you have an interest in attending the
conference or if you would like to arrange a meeting with International Stem
Cell Corporation’s management team please contact the conference
organizers. To register for the event visit
the conference website at http://convention.bio.org/register/
About
International Stem Cell Corporation
International Stem Cell
Corporation is focused on the therapeutic applications of human parthenogenetic
stem cells (hpSCs) and the development and commercialization of cell-based research
and cosmetic products. ISCO's core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence
avoiding ethical issues associated with the use or destruction of viable human
embryos. ISCO scientists have created the first parthenogenetic, homozygous
stem cell line that can be a source of therapeutic cells for hundreds of
millions of individuals of differing genders, ages and racial background with
minimal immune rejection after transplantation. hpSCs offer the potential to
create the first true stem cell bank, UniStemCellTM. ISCO also
produces and markets specialized cells and growth media for therapeutic
research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care
products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available
at www.internationalstemcell.com.
To
receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company
updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Contacts:
International Stem Cell Corporation
Dr. Simon Craw, Executive Vice President
Phone: 760-940-6383
No comments:
Post a Comment